INKT Key Statistics, Chart & Performance
The current stock price of INKT is 11.31 USD. In the past month the price decreased by -4.78%. In the past year, price increased by 2.46%.
INKT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is a bad performer in the overall market: 74.35% of all stocks are doing better.
INKT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INKT Forecast & Estimates
8 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 251.72% is expected in the next year compared to the current price of 11.31.
INKT Ownership
INKT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.93 | 383.716B | ||
| AMGN | AMGEN INC | 16.44 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.76 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.17 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.14 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INKT
Company Profile
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Company Info
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 23
Phone: 12129948250
MINK THERAPEUTICS INC / INKT FAQ
Can you describe the business of MINK THERAPEUTICS INC?
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
What is the stock price of MINK THERAPEUTICS INC today?
The current stock price of INKT is 11.31 USD. The price decreased by -1.39% in the last trading session.
What is the dividend status of MINK THERAPEUTICS INC?
INKT does not pay a dividend.
What is the ChartMill rating of MINK THERAPEUTICS INC stock?
INKT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
When does MINK THERAPEUTICS INC (INKT) report earnings?
MINK THERAPEUTICS INC (INKT) will report earnings on 2026-03-16, after the market close.
Can you provide the ownership details for INKT stock?
You can find the ownership structure of MINK THERAPEUTICS INC (INKT) on the Ownership tab.